Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin

BACKGROUND: Diabetes increases a patient’s risk of developing atrial fibrillation by 49%. Patients with nonvalvular atrial fibrillation are at a fivefold increased risk of stroke and die more frequently from vascular causes. We sought to evaluate the effectiveness and safety of rivaroxaban versus wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Coleman, Craig I., Costa, Olivia S., Brescia, Christopher W., Vardar, Burcu, Abdelgawwad, Khaled, Sood, Nitesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913443/
https://www.ncbi.nlm.nih.gov/pubmed/33637082
http://dx.doi.org/10.1186/s12933-021-01250-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913443/
https://www.ncbi.nlm.nih.gov/pubmed/33637082
http://dx.doi.org/10.1186/s12933-021-01250-5

Ejemplares similares